COMP <GO>
CAI vs MOH // RSI-14 & 200D SMA MOMENTUM
Caris Life Sciences Inc. (NASDAQ) VS. Molina Healthcare Inc (NYSE) • 15-METRIC TALLY: CAI 6
— MOH 6
▲ RSI-14 & 200D SMA MOMENTUM LEADER: CAI
LAST: $34.33 (-5.01%) • MKT CAP: $10.21B
rsi-technicals
67.6
LAST: $204.78 (+2.93%) • MKT CAP: $10.39B
rsi-technicals
46.2
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CAI VS. MOH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CAI | MOH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 13.10% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.40% | 17.20% | -12.80 | MOH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | 11.4x | +83.60 | MOH | /valuation <GO> |
| Free Cash Flow Yield | 0.65% | -6.12% | +6.77 | CAI | /fcf-yield <GO> |
| Operating Margin | 5.60% | 1.70% | +3.90 | CAI | /operating-margins <GO> |
| Net Profit Margin | -8.40% | 1.00% | -9.40 | MOH | /net-margins <GO> |
| Revenue Growth (YoY) | 97.00% | 11.70% | +85.30 | CAI | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 9.79 | 4.34 | +5.45 | CAI | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 4/9 | +4.00 | CAI | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 67.6 | 46.2 | +21.40 | CAI | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.91 | 0.94 | -0.03 | MOH | /macro-sensitivity <GO> |
| Forward P/E Multiple | 21.0x | 20.5x | +0.50 | MOH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.21B | $10.39B | -$172.2M | MOH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CAI REV | MOH REV | CAI GROSS % | MOH GROSS % | CAI FCF | MOH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $812.0M | $45.43B | — | 13.1% | $66.9M | -$636.0M |
| FY 2024 | $412.3M | $40.65B | — | 15.3% | -$253.6M | $544.0M |
| FY 2023 | $306.1M | $34.07B | — | — | -$289.9M | $128.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CAI // BETA 0.91
MOH // BETA 0.94